{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:09:26Z","timestamp":1791047366351,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100031293","name":"PureTech Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-025-03689-8","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T06:43:24Z","timestamp":1746686604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study"],"prefix":"10.1186","volume":"25","author":[{"given":"Camilla S.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Bisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Pardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Salisbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejaswini","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"9779","key":"3689_CR1","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, and the CAPACITY Study Group, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760\u20139.","journal-title":"Lancet."},{"issue":"22","key":"3689_CR2","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, and the ASCEND Study Group, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med."},{"issue":"22","key":"3689_CR3","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, and the INPULSIS Trial Investigators, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med."},{"issue":"1","key":"3689_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","volume":"5","author":"SD Nathan","year":"2017","unstructured":"Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33\u201341.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3689_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000397","volume":"6","author":"L Lancaster","year":"2019","unstructured":"Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019;6(1): e000397.","journal-title":"BMJ Open Respir Res"},{"issue":"12","key":"3689_CR6","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1513\/AnnalsATS.202001-035SD","volume":"17","author":"BR Wang","year":"2020","unstructured":"Wang BR, Edwards R, Freiheit EA, Ma Y, Burg C, de Andrade J, Lancaster L, et al. The Pulmonary Fibrosis Foundation Patient Registry Rationale, Design, and Methods. Ann Am Thorac Soc. 2020;17(12):1620\u20138.","journal-title":"Ann Am Thorac Soc."},{"issue":"11","key":"3689_CR7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1513\/AnnalsATS.201912-880OC","volume":"17","author":"ML Salisbury","year":"2020","unstructured":"Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, and IPF-PRO Registry principal investigators, et al. Antifibrotic drug use in patients with idiopathic pulmonary fibrosis Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020;17(11):1413\u201323.","journal-title":"Ann Am Thorac Soc."},{"issue":"7","key":"3689_CR8","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1513\/AnnalsATS.202007-901OC","volume":"18","author":"TM Dempsey","year":"2021","unstructured":"Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH. Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2021;18(7):1121\u20138.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"3689_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1513\/AnnalsATS.202308-697RL","volume":"21","author":"DA Shankar","year":"2024","unstructured":"Shankar DA, Hawkins F, Alysandratos KD, Wilson KC, Walkey AJ, Bosch NA, et al. Uptake of antifibrotics for patients with idiopathic pulmonary fibrosis: 2016\u20132022. Ann Am Thorac Soc. 2024;21(1):170\u20133.","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"3689_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.chest.2023.02.027","volume":"164","author":"B Kaul","year":"2023","unstructured":"Kaul B, Lee JS, Petersen LA, McCulloch C, Rosas IO, Bandi VD, et al. Disparities in antifibrotic medication utilization among veterans with idiopathic pulmonary fibrosis. Chest. 2023;164(2):441\u20139.","journal-title":"Chest"},{"issue":"3","key":"3689_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.amjmed.2019.08.032","volume":"133","author":"M Kalluri","year":"2020","unstructured":"Kalluri M, Luppi F, Ferrara G. What patients with idiopathic pulmonary fibrosis and caregivers want: Filling the gaps with patient reported outcomes and experience measures. Am J Med. 2020;133(3):281\u20139.","journal-title":"Am J Med"},{"issue":"1","key":"3689_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/resp.14154","volume":"27","author":"L Lancaster","year":"2022","unstructured":"Lancaster L, Bonella F, Inoue Y, Cottin V, Siddall J, Small M, Langley J. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology. 2022;27(1):66\u201375.","journal-title":"Respirology"},{"issue":"5","key":"3689_CR13","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1183\/13993003.01566-2015","volume":"47","author":"D Overgaard","year":"2016","unstructured":"Overgaard D, Kaldan G, Marsaa K, Nielsen TL, Shaker SB, Egerod I. The lived experience with idiopathic pulmonary fibrosis: a qualitative study. Eur Respir J. 2016;47(5):1472\u201380.","journal-title":"Eur Respir J"},{"issue":"3","key":"3689_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/resp.13414","volume":"24","author":"K Burnett","year":"2019","unstructured":"Burnett K, Glaspole I, Holland AE. Understanding the patient\u2019s experience of care in idiopathic pulmonary fibrosis. Respirology. 2019;24(3):270\u20137.","journal-title":"Respirology"},{"issue":"10","key":"3689_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","volume":"6","author":"D Visca","year":"2018","unstructured":"Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med. 2018;6(10):759\u201370.","journal-title":"Lancet Respir Med"},{"key":"3689_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12890-016-0171-y","volume":"16","author":"AM Russell","year":"2016","unstructured":"Russell AM, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients\u2019 perspectives of the disease and treatment. BMC Pulm Med. 2016;16:10.","journal-title":"BMC Pulm Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03689-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T06:43:24Z","timestamp":1746686604000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03689-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3689"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03689-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6190511\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both the qualitative and quantitative protocols were submitted to the Institutional Review Board Western-Copernicus Group (Puyallup, WA; references 1\u20131669153-1 and 1\u20131719988-1), and this study was determined exempt under 45 CFR \u00a7 46.104(d)(2). The study was conducted in accordance with the principles of the Declaration of Helsinki (Ethical Principles for Medical Research Involving Human Subjects). A third party vendor described risks to participation and obtained consent to participate in the qualitative interviews. For the on-line survey, consent was also obtained prior to participation (Additional file\n                      \n                      Survey Questionnaire).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.G., E.P, B.B. and F.S are current or former employees of PureTech Health and L.L and T.K are consultants to PureTech Health.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}